Brian Park, PharmD

Drug Information Specialist https://www.thecardiologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Metabolic

Tesomet Receives Orphan Drug Status for Hypothalamic Obesity

Brian Park, PharmD

July 29, 2021

Tesomet is an investigational fixed-dose combination therapy of tesofensine, a triple monoamine reuptake inhibitor, and metoprolol, a beta-1 selective blocker.

Metabolic

Extended-Release Exenatide Approved for Adolescents With T2D

Brian Park, PharmD

July 27, 2021

The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes.

Metabolic

FDA Requests Removal of Pregnancy Contraindication for Statins

Brian Park, PharmD

July 22, 2021

The FDA conducted a comprehensive review of all available data associated with the use of statins during pregnancy.

General Medicine

FDA Approves 15-Valent Pneumococcal Conjugate Vaccine Vaxneuvance

Brian Park, PharmD

July 21, 2021

Vaxneuvance consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F.

General Cardiology

Generic Version of Feraheme Now Available

Brian Park, PharmD

July 20, 2021

The first generic version of Feraheme (ferumoxytol injection) has been made available by Sandoz.

General Cardiology

Statin Use Linked to Reduced Death Risk in Hospitalized COVID-19 Patients

Brian Park, PharmD

July 19, 2021

Study authors analyzed data from 10,541 hospitalized patients with active COVID-19 disease to evaluate the relationship between the use of statins and COVID-19 outcomes.